PA8525701A1 - Compuestos con nucleos heterociclico-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso - Google Patents
Compuestos con nucleos heterociclico-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su usoInfo
- Publication number
- PA8525701A1 PA8525701A1 PA20018525701A PA8525701A PA8525701A1 PA 8525701 A1 PA8525701 A1 PA 8525701A1 PA 20018525701 A PA20018525701 A PA 20018525701A PA 8525701 A PA8525701 A PA 8525701A PA 8525701 A1 PA8525701 A1 PA 8525701A1
- Authority
- PA
- Panama
- Prior art keywords
- compounds
- pharmaceutical compositions
- heterociclic
- methods
- fluorene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
Abstract
SE DESCRIBEN LOS COMPUESTOS DE NUCLEOS HETEROCICLICOS-HIDROXIIMINO-FLUORENO QUE MODULAN Y/O INHIBEN LA ACTIVIDAD DE LAS PROTEINAS CINASAS. ESTOS COMPUESTOS Y LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SON CAPACES DE MEDIAR LA TRANSDUCCION DE LA SEÑAL DE LA TIROSINA CINASA PARA MODULAR Y/O INHIBIR LA PROLIFERACION DE LAS CELULAS INDESEABLES. LA INVENCION TAMBIEN SE DIRIGE AL USO TERAPEUTICO O PROFILACTICO DE LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS Y A LOS METODOS, MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE DICHOS COMPUESTOS, PARA EL TRATAMIENTO DEL CANCER Y LAS OTRAS ENFERMEDADES ASOCIADAS CON LA ANGIOGENESIS Y/O PROLIFERACION CELULAR INDESEABLE, TALES COMO RETINOPATIA DIABETICA, EL GLAUCOMA NEOVASCULAR, LA ARTRITIS REUMATOIDE Y LA SORIASIS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22480500P | 2000-08-18 | 2000-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8525701A1 true PA8525701A1 (es) | 2002-04-25 |
Family
ID=22842288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20018525701A PA8525701A1 (es) | 2000-08-18 | 2001-08-17 | Compuestos con nucleos heterociclico-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso |
Country Status (16)
Country | Link |
---|---|
US (1) | US6462060B2 (es) |
EP (1) | EP1309563B1 (es) |
JP (1) | JP2004506720A (es) |
AR (1) | AR032891A1 (es) |
AT (1) | ATE295354T1 (es) |
AU (1) | AU2001279090A1 (es) |
BR (1) | BR0113258A (es) |
CA (1) | CA2411924A1 (es) |
DE (1) | DE60110802T2 (es) |
ES (1) | ES2238463T3 (es) |
GT (1) | GT200100170A (es) |
MX (1) | MXPA03001452A (es) |
PA (1) | PA8525701A1 (es) |
PE (1) | PE20020289A1 (es) |
SV (1) | SV2003000603A (es) |
WO (1) | WO2002016326A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
JP4502641B2 (ja) * | 2002-01-24 | 2010-07-14 | ティルタン ファーマ リミテッド | 抗癌組み合わせおよびその使用方法 |
CA2542638A1 (en) * | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
WO2006056889A2 (en) * | 2004-10-06 | 2006-06-01 | Tiltan Pharma Ltd | Method and composition for enhancing anti-angiogenic therapy |
ES2356068T3 (es) | 2005-03-29 | 2011-04-04 | Icos Corporation | Derivados de heteroaril urea utiles para inhibir chk1. |
WO2007026720A1 (ja) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | 縮環ピラゾール誘導体 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
ATE262902T1 (de) | 1994-11-10 | 2004-04-15 | Millennium Pharm Inc | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
CN1160309C (zh) * | 1996-05-30 | 2004-08-04 | 赫彻斯特马里恩鲁斯公司 | 烷氧基氨基取代的芴酮以及它们作为蛋白激酶c抑制剂的用途 |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
CA2294244A1 (en) | 1997-07-12 | 1999-01-21 | Cancer Research Campaign Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
ES2206997T3 (es) | 1997-10-06 | 2004-05-16 | ABBOTT GMBH & CO. KG | Derivados de indeno(1,2-c)-,de nafto(1,2-c),y de benzo(6,7)cicloepta(1,2-c)pirazol. |
ES2267873T3 (es) | 1997-10-27 | 2007-03-16 | Agouron Pharmaceuticals, Inc. | Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina. |
ATE355841T1 (de) | 1997-12-13 | 2007-03-15 | Bristol Myers Squibb Co | Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer |
US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
DK1056745T3 (da) | 1998-02-26 | 2004-10-25 | Aventis Pharma Inc | 6,9-Disubstituerede 2-[trans-(4-aminocyklohexyl)amino]puriner |
BR9909597A (pt) | 1998-04-21 | 2001-10-02 | Du Pont Pharm Co | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
DE69933680T2 (de) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
ATE336484T1 (de) | 1998-08-29 | 2006-09-15 | Astrazeneca Ab | Pyrimidine verbindungen |
US6316603B1 (en) * | 1998-09-08 | 2001-11-13 | Agouron Pharmaceuticals, Inc. | Modifications of the VEGF receptor-2 protein and methods of use |
PL348210A1 (en) * | 1998-11-06 | 2002-05-06 | Basf Ag | Tricyclic pyrazole derivatives |
-
2001
- 2001-07-31 AT AT01957334T patent/ATE295354T1/de not_active IP Right Cessation
- 2001-07-31 MX MXPA03001452A patent/MXPA03001452A/es active IP Right Grant
- 2001-07-31 JP JP2002521202A patent/JP2004506720A/ja not_active Withdrawn
- 2001-07-31 BR BR0113258-0A patent/BR0113258A/pt not_active IP Right Cessation
- 2001-07-31 CA CA002411924A patent/CA2411924A1/en not_active Abandoned
- 2001-07-31 WO PCT/US2001/023897 patent/WO2002016326A1/en active IP Right Grant
- 2001-07-31 EP EP01957334A patent/EP1309563B1/en not_active Expired - Lifetime
- 2001-07-31 DE DE60110802T patent/DE60110802T2/de not_active Expired - Fee Related
- 2001-07-31 AU AU2001279090A patent/AU2001279090A1/en not_active Abandoned
- 2001-07-31 ES ES01957334T patent/ES2238463T3/es not_active Expired - Lifetime
- 2001-08-14 PE PE2001000808A patent/PE20020289A1/es not_active Application Discontinuation
- 2001-08-15 AR ARP010103906A patent/AR032891A1/es unknown
- 2001-08-16 US US09/930,255 patent/US6462060B2/en not_active Expired - Fee Related
- 2001-08-17 PA PA20018525701A patent/PA8525701A1/es unknown
- 2001-08-17 GT GT200100170A patent/GT200100170A/es unknown
- 2001-08-17 SV SV2001000603A patent/SV2003000603A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2004506720A (ja) | 2004-03-04 |
MXPA03001452A (es) | 2004-05-04 |
US20020049238A1 (en) | 2002-04-25 |
DE60110802T2 (de) | 2005-10-06 |
CA2411924A1 (en) | 2002-02-28 |
GT200100170A (es) | 2002-05-16 |
BR0113258A (pt) | 2003-07-15 |
SV2003000603A (es) | 2003-01-13 |
WO2002016326A1 (en) | 2002-02-28 |
DE60110802D1 (de) | 2005-06-16 |
AU2001279090A1 (en) | 2002-03-04 |
ES2238463T3 (es) | 2005-09-01 |
ATE295354T1 (de) | 2005-05-15 |
PE20020289A1 (es) | 2002-05-27 |
US6462060B2 (en) | 2002-10-08 |
EP1309563A1 (en) | 2003-05-14 |
AR032891A1 (es) | 2003-12-03 |
EP1309563B1 (en) | 2005-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8510201A1 (es) | Compuestos de amida y composiciones farmacèuticas para inhibir proteinquinasas, y su modo de empleo | |
DOP2001000120A (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar e inhibir la proliferación celular | |
UY26190A1 (es) | Compuestos de tiazol y composiciones farmacéuticas para inhibir a las proteinquinasas y métodos para su utilización | |
PA8592901A1 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso | |
UY26231A1 (es) | Compuestos de indazol y composiciones farmaceuticas para la inhibicion de proteina kinasa y metodo para su uso. bajo ley 17.164 | |
UY28442A1 (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y métodos para intervenir en o inhibir la proliferacion celular | |
GT200400136A (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular. | |
PA8550101A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización | |
TWI262914B (en) | Compounds and pharmaceutical compositions for inhibiting protein kinases | |
SV1999000016A (es) | Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv | |
AR007855A1 (es) | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen | |
GT200100061A (es) | Compuestos y composiciones farmaceuticas y metodos para inhibir kinasas proteinicas. | |
UY26877A1 (es) | Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes | |
PA8525701A1 (es) | Compuestos con nucleos heterociclico-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso | |
BR0304963A (pt) | Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças | |
UY26888A1 (es) | Compuestos con núcleos heterocíclicos-hidroximino-fluoreno y las composiciones farmacéuticas para la inhibición de las proteínas cinasas y los métodos para su uso | |
UY26547A1 (es) | Compuestos de amida y composiciones farmacéuticas para inhibir proteinquinasas, y su modo de empleo | |
UY26543A1 (es) | Compuestos, composiciones farmacéuticas de indazol y métodos para mediar o inhibir la proliferación celular. | |
ECSP003556A (es) | Compuestos de indazole y composiciones farmaceuticas para la inhibicion de proteina kinasa y metodos para su uso | |
DOP2004000953A (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular. | |
DOP2003000788A (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso | |
UY26667A1 (es) | Compuestos, composiciones farmacéuticas y métodos para inhibir kinasas proteínicas |